EVERSANA and Pulse Infoframe Join Forces to Enhance Real-World Evidence Generation in Biopharma

Strategic Collaboration for Enhanced Solutions in Biopharma

EVERSANA, a recognized leader in technology-enabled commercialization services within the biopharmaceutical realm, has formally declared a strategic partnership with Pulse Infoframe. This collaboration aims to bolster the capabilities of both entities in the generation and utilization of real-world evidence (RWE) and health economics and outcomes research (HEOR). By combining EVERSANA's end-to-end commercialization expertise with Pulse Infoframe’s advanced RWE platform, the partnership seeks to create a dynamic evidence engine for pharmaceutical and medical device manufacturers.

The key highlight of this partnership is its ability to manage the entire lifecycle of evidence generation. This spans from global site-network assessments and feasibility studies to the design of registries and natural history studies. The collaboration further emphasizes direct data capture from sites and patients, culminating in Health Technology Assessment (HTA)-grade reporting and strategies tailored for reimbursement. This comprehensive approach not only serves regulatory bodies and health technology assessors but also supports the commercial objectives of the clients involved.

Mark Thierer, CEO of EVERSANA, emphasized the critical nature of real-world evidence in navigating the complexities of market access as companies strive to introduce innovative therapies. He stated, “Our collaboration harnesses the robust registry expertise from Pulse Infoframe particularly in specialized areas such as rare diseases and oncology, enabling us to deliver unparalleled solutions to our clients, thus enhancing market access.”

By merging their strengths, EVERSANA and Pulse Infoframe are set to offer a seamless continuum of evidence generation, facilitating study design, global assessments, and sophisticated external control methodology. This innovative approach not only promises increased efficiency but also assures enhanced data quality and scalability across global markets.

Femida Gwadry-Sridhar, CEO of Pulse Infoframe, shared insights on their platform’s capabilities, stating, “Our infrastructure is designed to produce regulatory-grade evidence from sites and patients directly. Partnering with EVERSANA enriches the evidence with critical insights required for regulatory, reimbursement, and commercial decision-making on a global scale.”

This partnership is expected to gain significant visibility at the upcoming ISPOR Europe 2026 event, scheduled for November 8-11 in Vienna, Austria.

About EVERSANA

EVERSANA stands out as the leading independent provider of comprehensive services across the life sciences industry. With solutions that prioritize patient experiences throughout the entire product lifecycle, EVERSANA is committed to delivering sustainable value to patients, prescribers, channel partners, and payers. Currently, they serve over 650 organizations ranging from innovative startups to well-established pharmaceutical companies, enhancing life sciences solutions for a healthier global community.

About Pulse Infoframe

Pulse Infoframe is recognized as a pioneering partner in the field of real-world data and evidence generation, offering its expertise to clients across the life sciences and healthcare sectors. Through their proprietary platform, they excel in conducting registries and natural history studies, positioning themselves as a premier source for regulatory-grade data derived directly from sites and patients.

In summary, the EVERSANA and Pulse Infoframe partnership represents a significant advancement in the capability to generate reliable evidence that is essential for regulatory compliance and effective market access strategies in today's biopharmaceutical landscape.